MarginsXMarginsX
Home › Markets › Health Care › MYGN

Myriad Genetics Inc. (MYGN)

MYGN trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$5.57
-1.59% on the day
Market cap
$534.3M
Small cap
Revenue · 2025
$824.5M
-1.6% on 2024
Net income · 2025
-$365.9M
-44.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/899923/000089992326000018/0000899923-26-000018-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerMYGN on Nasdaq
SectorHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
CountryUnited States
IPO year1995
SEC CIK0000899923
SEC industry codeIn Vitro & In Vivo Diagnostic Substances
Incorporated inDE

Financials · 2025

LineValue
Revenue$824.5M
Net income-$365.9M
Operating income-$387.2M
Net margin-44.4%
Operating margin-47.0%
Revenue growth-1.6%
Cash$149.6M
Total assets$706.6M
P/E (computed)Net income was not positive
P/S (computed)0.6×

Warning signs

Cash runway
64.6 months
$107.1M cash at September 30, 2026
Share count, 1 year
+2.9%
2025-10-31 to 2026-10-30 · +16.7% over 3 years
Going-concern doubt
No
10-Q filed November 6, 2026
Insider net buying, 12 months
$655K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-06
Cash and burn$107.1M cash; operating cash flow -$5.0M a quarter.Report 2026-09-30
Shares outstanding95,922,196 (2026-10-30); 93,213,722 a year earlier; 82,198,203 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-02-24
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Salt Lake City, Utah, United StatesPCAOB Form AP 2026-03-11
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $722K, sold $67K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q1 2027
2026-09-30
$202.7M-$43.9M-$6.5M$107.1M$121.1M$803.6M10-Q 2026-11-06
Q4 2026
2026-06-30
$190.7M-$43.2M-$8.3M$115.2M$120.7M$806.6M10-Q 2026-07-31
Q3 2026
2026-03-31
$200.4M-$34.1M-$15.7M$124.4M$120.3M$829.0M10-Q 2026-05-06
Q2 2026
2025-12-31
$209.8M-$7.9M$10.6M$149.6M$119.9M$824.5M10-K 2026-02-24
Q1 2026
2025-09-30
$205.7M-$27.4M$21.1M$145.4M$119.5M$825.3M10-Q 2026-11-06
Q4 2025
2025-06-30
$213.1M-$330.5M-$13.6M$74.4M$59.4M$832.9M10-Q 2026-07-31
Q3 2025
2025-03-31
$195.9M-$100K-$16.3M$91.8M$59.3M$831.3M10-Q 2026-05-06
Q2 2025
2024-12-31
$210.6M-$42.5M$6.6M$102.4M$39.6M$837.6M10-K 2026-02-24

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-03-04
Latest annual report10-K2026-02-24
Latest quarterly / interim10-Q2026-11-06
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-04-14

Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-4.4%
1 month+38.7%
3 months+78.5%
Year to date-8.0%
1 year-10.9%
From 52-week high-28.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances

TickerCompanyPriceDayMarket cap
NNNNAnbio Biotechnology$3.88+1.57%$558.3M
TKNOAlpha Teknova Inc.$7.77-5.36%$488.8M
QUITAchieve Life Sciences Inc. Common Shares$6.06-4.11%$666.8M
QDELQuidelOrtho Corporation$10.21-4.93%$700.5M
NTLAIntellia Therapeutics Inc.$9.86+1.65%$1.4B
CLDXCelldex Therapeutics Inc.$28.59-0.83%$2.2B
NEOGNeogen Corporation$10.88-3.12%$2.4B
ICCCImmuCell Corporation$11.42+6.23%$103.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier